Dermatophytosis

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis

Retrieved on: 
Wednesday, January 31, 2024

WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.

Key Points: 
  • WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.
  • Onychomycosis, or tinea unguium, is a fungal infection of the nail.
  • Onychomycosis can result in discoloration of the nail, onycholysis (nail separation from the nail bed), and nail plate thickening.
  • There have not been any new onychomycosis treatments approved by the FDA since 2014.4
    Centers for Disease Control and Prevention.

Ringworm fungal infections are common in the US and are becoming increasingly resistant to treatment – 6 questions answered

Retrieved on: 
Thursday, June 29, 2023

The World Health Organization considers antimicrobial resistance to be one of the most serious threats for global health.

Key Points: 
  • The World Health Organization considers antimicrobial resistance to be one of the most serious threats for global health.
  • Similar to the way bacteria have developed resistance to antibiotics, fungal infections throughout the world are becoming more drug-resistant and more deadly.

1. What is ringworm and how common is it?

    • However, a ringworm infection is a common infection of the skin caused by a fungus.
    • Experts state that about 20%-25% of the population will experience a ringworm infection at any given time.
    • Research shows that there are up to 40 types of fungus that can cause these ringworm infections, with the most common types being from the genuses Trichophyton, Microsporum or Epidermophyton.
    • Medical terms for ringworm are “tinea” and “dermatophytosis.” Tinea and dermatophytosis are synonyms for a contagious fungal infection of the skin.

2. How can you recognize ringworm?


    The hair, skin and nails of either fingers or toes are the likely landing spots for a ringworm infection. Signs and symptoms of an infection usually depend on which part of the body is affected, but generally may include hair loss and red, scaly, cracked skin. However, the most well-known sign that gives this infection its ironic and misplaced name – ringworm – is the hallmark ring-shaped rash.

3. How does ringworm spread?

    • Fungi can grow in two forms: yeasts, which are single round cells, and molds, which are made up of many cells forming long, thin, hairlike threads called hyphae.
    • Some of them can exhibit both forms of growth and thrive in decaying organic material like soil or a plant.
    • Ringworm occurs more frequently in tropical areas and during hot, humid summers.

4. How can you reduce the likelihood of getting it?

    • Some of the best ways to reduce or prevent a ringworm or other fungal infection include: – Wash hands with soap and warm water.
    • – Wear shoes and socks that are made of lightweight, breathable materials to reduce moisture.
    • – Avoid walking barefoot in wet or humid areas like locker rooms or public showers.

5. What treatments are there?

    • There are several treatment options, including antifungal medications prescribed by a physician or dermatologist or over-the-counter products sold as a cream or ointment.
    • Finally, in some cases a person may need to use antifungal shampoo and soap to clean themselves and sterilize bedding and clothing.

6. Why is antifungal resistance a growing problem?

    • Antimicrobial resistance, including antifungal resistance, is an ongoing global emergency.
    • Experts estimate that drug-resistant infections caused roughly 1.3 million deaths around the world in 2019.
    • Experts believe that inappropriate use of topical antifungal and corticosteroid medications is likely driving its spread.

LiVDerm Set To Launch Its Brand-New Online MOPD Foundations of Pediatric Dermatology Certificate Course

Retrieved on: 
Wednesday, June 7, 2023

This innovative course consists of six in-depth modules that look at the most common pediatric skin conditions clinicians come face-to-face with on a daily basis.

Key Points: 
  • This innovative course consists of six in-depth modules that look at the most common pediatric skin conditions clinicians come face-to-face with on a daily basis.
  • What makes this course even more appealing to busy health care professionals is the fact that it is fully online and self-paced.
  • Led by world-renowned medical, aesthetic, and pediatric dermatology experts, LiVDerm empowers providers to educate, collaborate, and engage.
  • With a multipronged approach to mastering the myriad of subspecialties within the field, LiVDerm provides innovative and integrated education across the dermatology spectrum.

Global Antifungal Agents Market Report 2022: Rising Incidences of Fungal Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 20, 2022

The global antifungal agents market is anticipated to grow at a significant CAGR of nearly 3.5% during the forecast period.

Key Points: 
  • The global antifungal agents market is anticipated to grow at a significant CAGR of nearly 3.5% during the forecast period.
  • Antifungal agents prevent and destroy the growth of fungi that are responsible for several diseases such as aspergillosis, ringworm, and skin infection, among others.
  • Antifungal agents are a class of drugs that are used to detect and eliminate fungal infections from the body with minimal side effects.
  • Another major factor contributing to the growth of the market is the rising incidences of fungal diseases.

ZYMOX Enzyme-Based Pet Health Products Introduces New Products for Cats and Kittens

Retrieved on: 
Monday, October 17, 2022

WESTMONT, Ill., Oct. 17, 2022 /PRNewswire/ -- Pet King Brands, Inc. announced they have expanded their veterinarian-recommended line of ZYMOX® Enzymatic Dermatology products to include three new products to provide relief of ear and skin conditions in cats and kittens. These new products will feature feline-focused packaging with images of cats and will include the prestigious Seal of Endorsement awarded by TICA, The International Cat Association.

Key Points: 
  • WESTMONT, Ill., Oct. 17, 2022 /PRNewswire/ -- Pet King Brands, Inc. announced they have expanded their veterinarian-recommended line of ZYMOX Enzymatic Dermatology products to include three new products to provide relief of ear and skin conditions in cats and kittens.
  • The line includes ZYMOX Enzymatic Ear Solution with 0.5% Hydrocortisone, ZYMOX Enzymatic Ear Cleanser, and the ZYMOX Enzymatic Topical Cream with 0.5% Hydrocortisone.
  • ZYMOX for Cats and Kittens has begun shipping and is available for purchase.
  • To learn more about the products, visit www.zymox.com
    Pet King Brands, the maker of ZYMOX Ear and Skin products, Oratene Brushless Oral Care, Equine Defense, and ZYLAFEN is a leader in veterinarian-approved pet products made in the USA.

Protein Hydrolysis Enzymes Market worth $2.9 Billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, October 11, 2022

CHICAGO, Oct. 11, 2022 /PRNewswire/ -- Protein Hydrolysis Enzymes Market is projected to reach USD 2.9 Billion by 2027, growing at a CAGR of 6.2% from 2022 to 2027, according to a new report by MarketsandMarkets.

Key Points: 
  • CHICAGO, Oct. 11, 2022 /PRNewswire/ -- Protein Hydrolysis Enzymes Market is projected to reach USD 2.9 Billion by 2027, growing at a CAGR of 6.2% from 2022 to 2027, according to a new report by MarketsandMarkets.
  • The diverse functions of protein hydrolysis enzymes in food, detergent, feed, pharmaceutical and Textile & leather applications is driving the growth of the market.
  • The Asia Pacific region is anticipated to witness the highest growth rate in the protein hydrolysis enzymes market during the forecast period.
  • In the Asia Pacific region, the protein hydrolysis enzymes market is largely driven by the increasing usage in detergents, pharmaceuticals, and food industries.

$25+ Billion Antifungal Drugs Markets, 2030 by Drug Class, Infection Type, Therapeutic Indications, Dosage Forms - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 8, 2022

The "Antifungal Drugs Market By Drug Class, By Infection Type, By Therapeutic Indications, By Dosage Forms: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antifungal Drugs Market By Drug Class, By Infection Type, By Therapeutic Indications, By Dosage Forms: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The anti-fungal drugs market was valued at $16,572.1 million in 2020, and is estimated to reach $25,045.20 million by 2030, growing at a CAGR of 3.9% from 2021 to 2030.
  • Moreover, the key players Pfizer Inc., Abbott Laboratories, and Bayer Ag provide numerous anti-fungal drugs that contribute toward the market growth.
  • The antifungal drugs market is segmented on the basis of drug type, therapeutic indication, infection type, and region.

Study into the Satisfaction Level of Veterinarians Regarding the Effects of Agaricus blazei mushroom, KA21 supplement on Dogs / Cats Malassezia and Dermatophytosis, Toei Shinyaku

Retrieved on: 
Friday, August 12, 2022

Toei Shinyaku conducted a survey to determine the effectiveness and veterinarian satisfaction level of Agaricus blazei KA21 supplement on Malassezia and dermatophytosis, and published the findings.

Key Points: 
  • Toei Shinyaku conducted a survey to determine the effectiveness and veterinarian satisfaction level of Agaricus blazei KA21 supplement on Malassezia and dermatophytosis, and published the findings.
  • The satisfaction level of veterinarians regarding the effects of Agaricus blazei, KA21 strain as a pet (cat/dog) supplement to treat itchiness, odor, hair loss, etc.
  • Agaricus blazei (also known as Agaricus blazei Murill, A. brasiliensis, A. subrufescens) is a medicinal mushroom.
  • Agaricus KA21 is Agaricus blazei KA21 strain cultivated outdoors in Brazil under direct sunlight.

DermBiont Announces Positive Phase 2 Clinical Trial Data Treating Seborrheic Keratosis with SM-020, the First and Only Targeted Topical Treatment for these Common Benign Tumors

Retrieved on: 
Thursday, June 23, 2022

SKs are benign clonal tumors of the skin that often appear over the age of thirty-five.

Key Points: 
  • SKs are benign clonal tumors of the skin that often appear over the age of thirty-five.
  • All three cohorts saw improvement and clearance of SKs, with the effect being most pronounced in the two 28-day treatment cohorts.
  • DermBiont plans to initiate a 100+ patient Phase 2 trial in early 2023, and Phase 3 trials could be initiated as early as Q1 2024.
  • DermBionts mission is to become the worlds leading precision dermatology company developing and commercializing targeted topical therapeutics that treat, cure, and prevent diseases.

Athlete's Foot (Tinea Pedis) Epidemiology Forecast/Research Report 2022-2032: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 4, 2022

This "Athlete's Foot (Tinea Pedis) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Athlete's Foot (Tinea Pedis) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This "Athlete's Foot (Tinea Pedis) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Athlete's Foot (Tinea Pedis) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Athlete's Foot (Tinea Pedis) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries.
  • The Athlete's Foot (Tinea Pedis) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM.
  • The Athlete's Foot (Tinea Pedis) epidemiology covered in the report provides historical as well as forecasted Athlete's Foot (Tinea Pedis) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.